Meeting
2014 ASCO Annual Meeting
Phase I trial of pomalidomide (P) in patients (pts) with relapsed and/or refractory (R/R) Waldenström's macroglobulinemia (WM).
Authors
Sheeba K. Thomas
The University of Texas MD Anderson Cancer Center, Houston, TX
Sheeba K. Thomas , A. Georgina Melendez , Lei Feng , Michael Wang , Sattva Swarup Neelapu , Jatin J. Shah , Robert Z. Orlowski , Donna M. Weber
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Plasma Cell Disorders
Clinical Trial Registration Number
NCT01198067
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 8536)
DOI
10.1200/jco.2014.32.15_suppl.8536
Abstract #
8536
Poster Bd #
16
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial.
First Author: Lorenzo Falchi
Poster
2013 ASCO Annual Meeting
Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial.
First Author: David Samuel DiCapua Siegel
Poster
2013 ASCO Annual Meeting
Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.
First Author: Sundar Jagannath
Poster
2013 ASCO Annual Meeting
MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).
First Author: Paul Gerard Guy Richardson